Muhammad Abdul-Ghani
The University of Texas Health Science Center at San Antonio · Diabetes Division, UTHSCSA
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Muhammad Abdul-Ghani as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 02:19 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT07056699 · SGLT2i, Pioglitazone, and Ketone Production in T1DThe University of Texas Health Science Center at San Antonio · recruiting · Type1diabetes · principal investigator
- Ph3NCT06246799 · Comparative Effectiveness of Two Initial Combination Therapies in Patients With Recent Onset DiabetesThe University of Texas Health Science Center at San Antonio · recruiting · Type 2 Diabetes (Adult Onset) · principal investigator
- Ph4NCT03193684 · Empagliflozin and Hepatic Glucose MetabolismThe University of Texas Health Science Center at San Antonio · completed · Hepatic Glucose Metabolism · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 02:19 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Comparative Effectiveness of Two Initial Combination Therapies in Patients with New Onset DiabetesR01DK097554 · NIDDK · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · fiscal years 2012 to 2026 · $684,914 awarded in 2026Grant number is on one of their registry trials
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- SGLT2 Inhibitors, Ketogenesis, and KetoacidosisR01DK024092 · NIDDK · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI RALPH A DEFRONZO · fiscal years 1986 to 2026Named on NCT07056699
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 02:19 UTC. The ranking covers the 200 most relevant of 40 PubMed records, and a shared surname and initials can bring in a namesake. All 40 on PubMed
- Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production.J Clin Invest · 2014671 citationsRCR 22.5
- SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study.Diabetes Care · 2016236 citationsRCR 8.9
- 230 citationsRCR 7.8
- Dapagliflozin Enhances Fat Oxidation and Ketone Production in Patients With Type 2 Diabetes.Diabetes Care · 2016184 citationsRCR 6.4
- 169 citationsRCR 5.6
- Dapagliflozin lowers plasma glucose concentration and improves β-cell function.J Clin Endocrinol Metab · 2015160 citationsRCR 5.5
- Empagliflozin Treatment Is Associated With Improved β-Cell Function in Type 2 Diabetes Mellitus.J Clin Endocrinol Metab · 201888 citationsRCR 3.5
- Effect of treatment with exenatide and pioglitazone or basal-bolus insulin on diabetic neuropathy: a substudy of the Qatar Study.BMJ Open Diabetes Res Care · 202067 citationsRCR 4.3
- Impaired early- but not late-phase insulin secretion in subjects with impaired fasting glucose.Acta Diabetol · 201153 citationsRCR 1.5
- Durability of Triple Combination Therapy Versus Stepwise Addition Therapy in Patients With New-Onset T2DM: 3-Year Follow-up of EDICT.Diabetes Care · 202148 citationsRCR 3.0